BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Pulse Biosciences (PLSE)Pulse BiosciencesConference / presentation

Preclinical evaluation of nPulse™ prototype endocardial catheters highlighted in session presentation HAYWARD, Calif. --(BUSINESS WIRE)--Oct. 8, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA

Related news

PLSEPulse Biosciences2026-09-15 11:00 EST

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

PLSEPulse Biosciences2026-10-14 11:00 EST

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

ACHCAcadia Healthcare2026-09-09 13:00 EST

Acadia Healthcare to Participate in 2026 Jefferies Healthcare Services and Technology Conference

IRTCiRhythm2026-08-26 20:05 EST

iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

ICUSeaStar Medical2026-09-29 12:36 EST

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

IARTIntegra LifeSciences2026-09-04 13:15 EST

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

TMCITreace Medical Concepts2026-09-17 21:16 EST

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

HYPRHyperfine2026-08-31 12:15 EST

Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

ATRCAtriCure2026-08-25 12:00 EST

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

PLSEPulse Biosciences2026-10-14 11:00 EST

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

PLSEPulse Biosciences2026-10-09 20:05 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PLSEPulse Biosciences2026-10-08 11:00 EST

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

PLSEPulse Biosciences2026-10-07 11:00 EST

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Stock data

Close
51.31 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States